Protecting the thymic epithelial cells and thymopoiesis during hematopoietic stem cell transplantation
ProtecTHY aims to uncover the protective mechanisms of the human thymus during alloHSCT to prevent thymic damage and improve outcomes through innovative research and clinical treatment assessment.
Projectdetails
Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a common, often last-resort treatment for haematological diseases, but it is plagued by long-term morbidity and high mortality. Direct alloHSCT-induced damage to the thymus and subsequent loss of thymopoiesis, i.e., the production of new T cells, is considered one of the main reasons for these complications.
Background
Our limited understanding of how the thymus is damaged during alloHSCT restricts the development of thymus-protecting protocols. The goal of ProtecTHY is to unravel the intrinsic protective mechanisms of the human thymus and assess how alloHSCT affects them, with the ultimate objective of devising measures to prevent thymic damage.
Methodology
We take advantage of an innovative whole organ culture system for the human thymus developed in my laboratory and our extensive pre-existing collection of human thymus tissue samples spanning a diverse age range. ProtecTHY specifically aims to:
- Discover how the thymus protects itself from external insults over the course of the human lifetime.
- Reveal how alloHSCT disrupts the human thymus microanatomy and how that damage can be prevented with a cellular therapy.
- Examine how thymic damage affects the circulating true naive T cells and if existing clinical treatments for alloHSCT complications can restore the loss of thymopoiesis.
Techniques
We will apply state-of-the-art spatial and single-cell multiomics to dissect these protective layers of the thymus both ex vivo and after alloreactive challenge in vitro. Moreover, by testing the effect of treatments already in clinical use, ProtecTHY can resolve their specific mechanisms of action and impact on the thymus.
Impact
Our results are thus directly translatable to the human condition and can direct future treatments to enhance outcomes following alloHSCT. As a translational immunologist and clinical microbiologist with extensive experience in human thymus research, I am well equipped to uncover the mechanisms of thymic protection.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.175.054 |
Totale projectbegroting | € 2.175.054 |
Tijdlijn
Startdatum | 1-1-2025 |
Einddatum | 31-12-2029 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- HELSINGIN YLIOPISTOpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantationRESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes. | ERC Starting... | € 1.500.000 | 2024 | Details |
MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus host disease and cure leukemia relapseThe "MICROBOTS" project aims to characterize gut microbiome signatures in allo-SCT patients to enhance antitumor responses and reduce GVHD through precision fecal microbiota transplantation. | ERC Consolid... | € 1.999.901 | 2024 | Details |
Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapseAlloCure aims to identify and target pathogenic signaling in immune and leukemia cells to develop personalized therapies that reduce mortality from GVHD and leukemia relapse post-allo-HCT. | ERC Advanced... | € 2.498.943 | 2023 | Details |
TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATIONFUN-HSC aims to identify and mimic maturation pathways of hematopoietic stem cells from pluripotent stem cells to create a reliable, clinically valuable source for diverse therapies. | ERC Consolid... | € 2.265.684 | 2024 | Details |
Preventing rejection and ensuring survival of graftsThis project aims to enhance organ transplant success by using Listeria monocytogenes to protect grafted cells from T-cell killing, reducing reliance on immunosuppressive drugs and improving patient outcomes. | ERC Proof of... | € 150.000 | 2025 | Details |
How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantation
RESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes.
MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus host disease and cure leukemia relapse
The "MICROBOTS" project aims to characterize gut microbiome signatures in allo-SCT patients to enhance antitumor responses and reduce GVHD through precision fecal microbiota transplantation.
Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapse
AlloCure aims to identify and target pathogenic signaling in immune and leukemia cells to develop personalized therapies that reduce mortality from GVHD and leukemia relapse post-allo-HCT.
TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION
FUN-HSC aims to identify and mimic maturation pathways of hematopoietic stem cells from pluripotent stem cells to create a reliable, clinically valuable source for diverse therapies.
Preventing rejection and ensuring survival of grafts
This project aims to enhance organ transplant success by using Listeria monocytogenes to protect grafted cells from T-cell killing, reducing reliance on immunosuppressive drugs and improving patient outcomes.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune systemi-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028. | EIC Accelerator | € 2.495.510 | 2023 | Details |
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical applicationThis project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer. | EIC Pathfinder | € 3.797.562 | 2022 | Details |
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemiaThe project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes. | EIC Transition | € 2.497.500 | 2023 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
Bottom-up manufacturing of artificial anti-tumor T cellsThe project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment. | EIC Pathfinder | € 3.391.796 | 2024 | Details |
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
i-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028.
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application
This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
The project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.
Bottom-up manufacturing of artificial anti-tumor T cells
The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.